NUVIGIL Jet Lag Disorder Data Presented at the SLEEP 2009 23rd Annual Meeting of the Associated Professional Sleep...(vide Cephalon's current expectations or ...),Health

Date:6/10/2009

vide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, development of potential pharmaceutical products, interpretation of clinical results, clinical development of NUVIGIL, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, sales and earnings guidance, and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.

    Contacts:
    Media:                      Investor Relations:
    Candace Steele              Chip Merritt
    610-727-6231 (office)       610-738-6376 (office)
    csteele@cephalon.com        cmerritt@cephalon.com

'/>"/>

SOURCE Cephalon, Inc. Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5
Related medicine news :

1. Cephalon Announces the Availability of NUVIGIL for the Treatment of Excessive Sleepiness Associated with Treated Obstructive Sleep Apnea, Shift Work Disorder and Narcolepsy
2. Courage Center Is First in Midwest to Offer Innovative Treatment for Movement Disorders
3. BayCare Health System Sleep Disorder Centers Offer Help for Sleepless Nights
4. Health Plans and IROs Can Work Together to Determine Proper Care for Eating Disorders
5. Heavy Periods May Be Due to a Clotting Disorder
6. Body and Weight Checking May Signify an Eating Disorder
7. Surveyed Psychiatrists and PCPs Expect to Increase Their First-Line Use of SNRIs Over the Next Two Years for the Treatment of Generalized Anxiety Disorder
8. Experts reach consensus on diagnosis and treatment of bleeding disorders in women
9. Schering-Plough Announces European Filing of SYCREST(R) (asenapine) for the Treatment of Schizophrenia and Bipolar I Disorder
10. Hopkins study: When adult patients have anxiety disorder, their children need help too
11. ADHD Treatment Guide: How to Safely, Effectively Use Medications and Non-Drug Therapies to Treat Attention Deficit Disorder